Independent association of extent of resection with survival in patients with malignant brain astrocytoma

Clinical article

Restricted access

Object

With recent advances in the adjuvant treatment of malignant brain astrocytomas, it is increasingly debated whether extent of resection affects survival. In this study, the authors investigate this issue after primary and revision resection of these lesions.

Methods

The authors retrospectively reviewed the cases of 1215 patients who underwent surgery for malignant brain astrocytomas (World Health Organization [WHO] Grade III or IV) at a single institution from 1996 to 2006. Patients with deep-seated or unresectable lesions were excluded. Based on MR imaging results obtained < 48 hours after surgery, gross-total resection (GTR) was defined as no residual enhancement, near-total resection (NTR) as having thin rim enhancement of the resection cavity only, and subtotal resection (STR) as having residual nodular enhancement. The independent association of extent of resection and subsequent survival was assessed via a multivariate proportional hazards regression analysis.

Results

Magnetic resonance imaging studies were available for review in 949 cases. The mean age and mean Karnofsky Performance Scale (KPS) score at time of surgery were 51 ± 16 years and 80 ± 10, respectively. Surgery consisted of primary resection in 549 patients (58%) and revision resection for tumor recurrence in 400 patients (42%). The lesion was WHO Grade IV in 700 patients (74%) and Grade III in 249 (26%); there were 167 astrocytomas and 82 mixed oligoastrocytoma. Among patients who underwent resection, GTR, NTR, and STR were achieved in 330 (35%), 388 (41%), and 231 cases (24%), respectively. Adjusting for factors associated with survival (for example, age, KPS score, Gliadel and/or temozolomide use, and subsequent resection), GTR versus NTR (p < 0.05) and NTR versus STR (p < 0.05) were independently associated with improved survival after both primary and revision resection of glioblastoma multiforme (GBM). For primary GBM resection, the median survival after GTR, NTR, and STR was 13, 11, and 8 months, respectively. After revision resection, the median survival after GTR, NTR, and STR was 11, 9, and 5 months, respectively. Adjusting for factors associated with survival for WHO Grade III astrocytoma (age, KPS score, and revision resection), GTR versus STR (p < 0.05) was associated with improved survival. Gross-total resection versus NTR was not associated with an independent survival benefit in patients with WHO Grade III astrocytomas. The median survival after primary resection of WHO Grade III (mixed oligoastrocytomas excluded) for GTR, NTR, and STR was 58, 46, and 34 months, respectively.

Conclusions

In the authors' experience with both primary and secondary resection of malignant brain astrocytomas, increasing extent of resection was associated with improved survival independent of age, degree of disability, WHO grade, or subsequent treatment modalities used. The maximum extent of resection should be safely attempted while minimizing the risk of surgically induced neurological injury.

Abbreviations used in this paper: AA = anaplastic astrocytoma; CI = confidence interval; GBM = glioblastoma multiforme; GTR = gross-total resection; KPS = Karnofsky Performance Scale; NTR = near-total resection; RR = relative risk; STR = subtotal resection; WHO = World Health Organization.

Article Information

Address correspondence to: Alfredo Quiñones-Hinojosa, M.D., Brain Tumor Stem Cell Laboratory, Department of Neurosurgery and Oncology, 1550 Orleans Street, Cancer Research Building II, Room 253, Baltimore, Maryland 21231. email: aquinon2@jhmi.edu.

Please include this information when citing this paper: publishedonline October 10, 2008; DOI: 10.3171/2008.4.17536.

© AANS, except where prohibited by US copyright law."

Headings

Figures

  • View in gallery

    Estimated Kaplan–Meier plot of survival after primary (upper) and revision resection (lower) of GBM. In both primary and secondary resection, patients who underwent NTR experienced an independent survival benefit compared with patients who underwent STR (p < 0.002). Patients who received GTR experienced an independent survival benefit compared with patients receiving NTR (p < 0.05). After primary GBM resection, the median survival after GTR, NTR, or STR was 13, 11, and 8 months, respectively. For revision surgery, median survival after GTR, NTR, and STR was 11, 9, and 5 months, respectively, from time of revision surgery. (GTR = no residual enhancement on MR; NTR = rim enhancement of resection cavity on MR imaging; STR = residual nodular enhancement).

  • View in gallery

    Estimated Kaplan–Meier plot of survival after primary resection of AAs (mixed oligoastrocytoma excluded). Both GTR and NTR were associated with a survival benefit versus STR. Gross-total resection versus NTR was not associated with improved survival. After GTR, NTR, or STR, median survival was 58, 46, and 34 months, respectively. The 5-year survival for patients undergoing GTR, NTR, and STR was 42, 41, and 12%, respectively.

References

1

Barker FG IIPrados MDChang SMGutin PHLamborn KRLarson DA: Radiation response and survival time in patients with glioblastoma multiforme. J Neurosurg 84:442 4481996

2

Berman JIBerger MSChung SWNagarajan SSHenry RG: Accuracy of diffusion tensor magnetic resonance imaging tractography assessed using intraoperative subcortical stimulation mapping and magnetic source imaging. J Neurosurg 107:4884942007

3

Brem HPiantadosi SBurger PCWalker MSelker RVick NA: Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-Brain Tumor Treatment Group Lancet 345:100810121995

4

Buckner JC: Factors influencing survival in high-grade gliomas. Semin Oncol 30:10142003

5

Butowski NLamborn KRBerger MSPrados MDChang SM: Historical controls for phase II surgically based trials requiring gross total resection of glioblastoma multiforme. J Neurooncol 85:87942007

6

Chang SMParney IFHuang WAnderson FA JrAsher ALBernstein M: Patterns of care for adults with newly diagnosed malignant glioma. JAMA 293:5575642005

7

Claes AIdema AJWesseling P: Diffuse glioma growth: a guerilla war. Acta Neuropathol 114:4434582007

8

Curran WJ JrScott CBHorton JNelson JSWeinstein ASFischbach AJ: Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85:7047101993

9

Dandy WE: Removal of right cerebral hemisphere for certain tumors with hemiplegia. JAMA 90:8238251928

10

DeAngelis LM: Brain tumors. N Engl J Med 344:1141232001

11

Dinapoli RPBrown LDArusell RMEarle JDO'Fallon JRBuckner JC: Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for highgrade glioma. J Clin Oncol 11:131613211993

12

Guggisberg AGHonma SMFindlay AMDalal SSKirsch HEBerger MS: Mapping functional connectivity in patients with brain lesions. Ann Neurol 63:1932032007

13

Hentschel SJLang FF: Current surgical management of glioblastoma. Cancer J 9:1131252003

14

Hess KR: Extent of resection as a prognostic variable in the treatment of gliomas. J Neurooncol 42:2272311999

15

House MGGonen MJarnagin WRD'Angelica MDematteo RPFong Y: Prognostic significance of pathologic nodal status in patients with resected pancreatic cancer. J Gastrointest Surg 11:154915552007

16

Jackson RJFuller GNAbi-Said DLang FFGokaslan ZLShi WM: Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-oncol 3:1932002001

17

Keles GEChang EFLamborn KRTihan TChang CJChang SM: Volumetric extent of resection and residual contrast enhancement on initial surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. J Neurosurg 105:34402006

18

Lacroix MAbi-Said DFourney DRGokaslan ZLShi WDeMonte F: A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95:1901982001

19

Lamborn KRChang SMPrados MD: Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro-oncol 6:2272352004

20

Laws ERParney IFHuang WAnderson FMorris AMAsher A: Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg 99:4674732003

21

Lawson HCSampath PBohan EPark MCHussain NOlivi A: Interstitial chemotherapy for malignant gliomas: the Johns Hopkins experience. J Neurooncol 83:61702007

22

Louis DNOhgaki HWiestler ODCavenee WKBurger PCJouvet A: The 2007 WHO Classification of Tumours of the Central Nervous System. Acta Neuropathol 114:971092007

23

Metcalfe SEGrant R: Biopsy versus resection for malignant glioma. Cochrane Database Syst Rev 3:CD0020342005

24

Muragaki YIseki HMaruyama TKawamata TYamane FNakamura R: Usefulness of intraoperative magnetic resonance imaging for glioma surgery. Acta Neurochir Suppl 98:67752006

25

Nazzaro JMNeuwelt EA: The role of surgery in the management of supratentorial intermediate and high-grade astrocytomas in adults. J Neurosurg 73:3313441990

26

Ng WHWan GQToo HP: Higher glioblastoma tumour burden reduces efficacy of chemotherapeutic agents: in vitro evidence. J Clin Neurosci 14:2612662007

27

Pang BCWan WHLee CKKhu KJNg WH: The role of surgery in high-grade glioma–is surgical resection justified? A review of the current knowledge. Ann Acad Med Singapore 36:3583632007

28

Pirzkall ALi XOh JChang SBerger MSLarson DA: 3D MRSI for resected high-grade gliomas before RT: tumor extent according to metabolic activity in relation to MRI. Int J Radiat Oncol Biol Phys 59:1261372004

29

Pope WBSayre JPerlina AVillablanca JPMischel PSCloughesy TF: MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol 26:246624742005

30

Quigley MRMaroon JC: The relationship between survival and the extent of the resection in patients with supratentorial malignant gliomas. Neurosurgery 29:3853891991

31

Schiffbauer HBerger MSFerrari PFreudenstein DRowley HARoberts TP: Preoperative magnetic source imaging for brain tumor surgery: a quantitative comparison with intraoperative sensory and motor mapping. J Neurosurg 97:1333 13422002

32

Simpson JRHorton JScott CCurran WJRubin PFischbach J: Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys 26:2392441993

33

Sneed PKGutin PHLarson DAMalec MKPhillips TLPrados MD: Patterns of recurrence of glioblastoma multiforme after external irradiation followed by implant boost. Int J Radiat Oncol Biol Phys 29:7197271994

34

Stewart LA: Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359:101110182002

35

Stupp RMason WPvan den Bent MJWeller MFisher BTaphoorn MJ: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987 9962005

36

Tait MJPetrik VLoosemore ABell BAPapadopoulos MC: Survival of patients with glioblastoma multiforme has not improved between 1993 and 2004: analysis of 625 cases. Br J Neurosurg 21:4965002007

37

Vecht CJAvezaat CJvan Putten WLEijkenboom WMStefanko SZ: The influence of the extent of surgery on the neurological function and survival in malignant glioma A retrospective analysis in 243 patients. J Neurol Neurosurg Psychiatry 53:4664711990

38

Walker JAQuinones-Hinojosa ABerger MS: Intraoperative speech mapping in 17 bilingual patients undergoing resection of a mass lesion. Neurosurgery 54:1131182004

39

Westphal MRam ZRiddle VHilt DBortey E: Gliadel wafer in initial surgery for malignant glioma: long-term followup of a multicenter controlled trial. Acta Neurochir (Wien) 148:2692752006

40

Whittle IRLyles SWalker M: Gliadel therapy given for first resection of malignant glioma: a single centre study of the potential use of Gliadel. Br J Neurosurg 17:3523542003

41

Yoshimoto MTada KNishimura SMakita MIwase TKasumi F: Favourable long-term results after surgical removal of lung metastases of breast cancer. Breast Cancer Res Treat [epub ahead of print]2007

TrendMD

Cited By

Metrics

Metrics

All Time Past Year Past 30 Days
Abstract Views 5 5 5
Full Text Views 95 95 48
PDF Downloads 75 75 52
EPUB Downloads 0 0 0

PubMed

Google Scholar